Session Information
ASHP Summer Meeting 2006
Click here to go to the previous page
Critically Evaluating Evidence Addressing Current Controversies ? Aggressive Lipid Lowering and Intensive Heart Failure Pharmacotherapy
Track:
Sessions
Program Code: 121-L01
Date: Monday, June 26, 2006
Time: 2:00 PM to 5:00 PM
SPEAKER(S):
Robert Lee Page II, Pharm.D., Associate Professor, University of Colorado Health Sciences Center
Description
Learning Objectives:
Review evidence-based pharmacotherapy recommendations for dyslipidemia and heart failure.
Compare and contrast recent evidence from prospective clinical trials evaluating aggressive lipid lowering (e.g., TNT, IDEAL, PROVE-IT).
Compare and contrast recent evidence from prospective clinical trials evaluating intensive heart failure pharmacotherapy (e.g., Elite-II, VALHEFT, CHARM).
Using a systematic approach, provide evidence-based recommendations for aggressive lipid lowering and intensive heart failure pharmacotherapy that can be applied to a health system.
Review evidence-based pharmacotherapy recommendations for dyslipidemia and heart failure.
Compare and contrast recent evidence from prospective clinical trials evaluating aggressive lipid lowering (e.g., TNT, IDEAL, PROVE-IT).
Compare and contrast recent evidence from prospective clinical trials evaluating intensive heart failure pharmacotherapy (e.g., Elite-II, VALHEFT, CHARM).
Using a systematic approach, provide evidence-based recommendations for aggressive lipid lowering and intensive heart failure pharmacotherapy that can be applied to a health system.
| No items are available for this session. |